What Phytome Life Sciences does

Phytome Life Sciences is a London, United Kingdom-based pharmaceutical company founded in 2018 by Sebastian Vaughan, who serves as Founder and CEO. The firm develops plant-derived biotherapeutics, with stated positioning toward addressing unmet medical needs. It operates as a privately held for-profit entity with a small team of 11-50 employees. The therapeutic hypothesis — using botanical sources as the basis for biologic drug candidates — places the company within the broader plant-derived pharma / phytopharmaceutical subsegment, a category that has produced approved products in specific indications but remains less established than synthetic biologics in mainstream pharma pipelines.

Publicly available information on the company is extremely limited. The company website (phytomelife.com) currently returns only a verification/loader page with no substantive content, and the firmographic and supplementary data sources contain no product portfolio, clinical pipeline details, funding history, partnerships, customer references, pricing, geographic footprint, certifications, intellectual property disclosures, or commercial activity. No management team beyond the founder is listed, no subsidiary or corporate structural history is recorded, and no investor disclosures or financial metrics are available. This data thinness prevents assessment of pipeline stage (whether the company is discovery, preclinical, or clinical), target indications, modality specifics (small molecules vs. complex biologics vs. extracts), regulatory milestones, capital base, or commercialization pathway.

Given the founder-led structure and small headcount over a five-plus-year operating history with no visible external capital or partnership events, the operating model most consistent with available evidence is a lean, internally funded early-stage research effort rather than a venture-backed, milestone-driven development program. Any deeper analysis of go-to-market, revenue mechanics, customer base, or competitive position requires primary-source diligence beyond the scope of available data.

Name

Phytome Life Sciences

Website

https://phytomelife.com

Company type

Private

Founded year

2018

Headcount range

11–50 employees

Short description

London-based pharmaceutical company founded in 2018 that develops plant-derived biotherapeutics for populations with unmet medical needs; privately held, founder-led (Sebastian Vaughan), with a small early-stage R&D team of 11-50 employees.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Phytogenics & Botanicals (Essential Oils, Herbs, Saponins) (AFADALAN)

Keywords

• Plant-derived therapeutics
• Biopharmaceutical development
• Botanical drug discovery
• Plant-based medicines
• Biotherapeutic research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Core offering

Phytome Life Sciences is a pharmaceutical company developing plant-derived biotherapeutics targeted at poorly served patient populations. The company conducts discovery and development work to translate botanical materials into therapeutic drug candidates. It operates as a private London-based R&D entity founded in 2018.

Differentiator

Problem solved

Functional benefit

Products and services

• Plant-derived biotherapeutic pipeline

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Zelira Therapeutics: Clinical-stage company developing plant-derived cannabinoid medicines for chronic conditions. Similar botanical-pharma positioning, comparable team size, and parallel regulatory strategy.
• InMed Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-based therapies, including proprietary manufacturing methods for plant-derived compounds. Closely comparable in scale, modality, and plant-based pipeline orientation.
• Botanix Pharmaceuticals: Focused on cannabis-derived pharmaceutical products, particularly in dermatology. Comparable in leveraging plant-derived APIs through clinical development and has reached Phase 2/3 readouts, illustrating a viable path to value.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer of plant-derived cannabinoid therapeutics (Epidiolex), acquired by Jazz Pharmaceuticals for $7.2B. Most directly comparable peer — same plant-derived small-molecule therapeutic model, validated regulatory pathway, and global commercialization.
• Ananda Scientific: Pharmaceutical company developing CBD-based therapeutics using a proprietary delivery platform. Comparable in focusing exclusively on plant-derived pharmaceutical candidates, with clinical-stage assets in pain and inflammatory conditions.

Broad incumbents

• Jazz Pharmaceuticals: Global biopharmaceutical company whose acquisition of GW Pharma validated the plant-derived therapeutic category. Represents the most likely strategic acquirer and a benchmark for the value ceiling of the category.
• Pfizer: Major pharmaceutical company with active programs in natural-product-derived therapeutics and global-health initiatives relevant to Phytome's underserved-patient mission. Potential partner or acquirer for late-stage assets.

Others

• DNDi (Drugs for Neglected Diseases initiative): Non-profit R&D organization developing treatments for neglected diseases, often in partnership with smaller biotechs. Highly relevant ecosystem participant given Phytome's stated mission focus on therapeutics for poor and underserved populations.

Emerging players

• Artelo Biosciences: Clinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics. Comparable in size, stage, and plant-derived therapeutic modality, with overlapping indications in oncology and inflammation.
• Emerald Health Pharmaceuticals: Develops novel drug candidates derived from botanical sources for CNS and inflammatory diseases. Smaller and earlier-stage but comparable in the botanical-to-pharma transition thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/PhytomeLife
• Facebookfacebook.com/PhytomeLife

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phytome Life Sciences